Women presenting with an asymptomatic hepatic cell adenoma under 5 cm represent a distinct clinical subgroup where a conservative, evidence-guided first-line strategy is appropriate. Key patient-specific factors shape the initial management approach in this setting.

Clinical Scenario

Female patients with a confirmed hepatic adenoma less than 5 cm in size can be monitored and initially managed conservatively, provided that imaging does not raise concern for a higher-risk subtype. Exogenous hormonal exposure and body weight are among the factors evaluated in this population.

Treatment Approach (Partial Overview)

The first-line strategy targets modifiable hormonal and lifestyle factors identified at presentation. The complete protocol specifies what is recommended, for whom, and under what conditions.

Full clinical details, structured recommendations, and the complete algorithm are available in the protocol below.

References

DOI: 10.14309/ajg.0000000000002857

Females with asymptomatic HCAs diagnosed at <5 cm in size can be monitored and initially managed conservatively unless imaging prompts concerns for b-catenin mutated subtype.
In women with hepatic adenomas <5 cm, we suggest discontinuation of exogenous hormones and advise weight loss, if applicable, for overweight or obese individuals (conditional recommendation, very low level of evidence).
The use of exogenous hormonal therapy should be discontinued.
In the case of an elevated body mass index, weight loss should be encouraged, although there is no specific established weight loss target for adenoma regression.
Repeat contrast-enhanced MRI should be performed after 6 months to assess for stability or regression of the adenoma, regardless of subtype.

View source ↗

Treatment of Liver Cell Adenoma in Women with Hepatic Adenoma Less Than 5 cm

References